Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
1.670
-0.010 (-0.60%)
At close: Jun 17, 2026, 4:00 PM EDT
1.700
+0.030 (1.80%)
After-hours: Jun 17, 2026, 7:41 PM EDT
BDTX Revenue
In the year 2025, Black Diamond Therapeutics had annual revenue of $70.00M.
Revenue (ttm)
$70.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
95.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 37.16M |
| Pelthos Therapeutics | 27.70M |
| Atara Biotherapeutics | 23.14M |
| Seer, Inc. | 15.17M |
| Cibus | 3.64M |
| Cardiff Oncology | 525.00K |
BDTX News
- 14 days ago - Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 26 days ago - Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 27 days ago - Black Diamond Therapeutics Transcript: Study result - Transcripts
- 27 days ago - Black Diamond Therapeutics Press release: Study result - Filings
- 27 days ago - Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - GlobeNewsWire
- 27 days ago - Black Diamond Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - GlobeNewsWire
- 5 weeks ago - Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire